Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
96 studies found for:    Fabry Disease
Show Display Options
Rank Status Study
21 Completed An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
22 Recruiting Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
Conditions: Fabry Disease;   Neuropathic Pain
Interventions: Drug: Gabapentin;   Drug: placebo
23 Completed Dosing Study of Replagal in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
24 Not yet recruiting Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150 mg
25 Completed Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
Condition: Fabry Disease
Intervention:
26 Unknown  Viennese Prevalence Study of Anderson-Fabry Disease
Conditions: Fabry Disease;   Left Ventricular Hypertrophy
Intervention:
27 Completed Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: Replagal (Agalsidase Alfa);   Drug: Replagal
28 Completed Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
29 Unknown  Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers
Conditions: Fabry Disease, Cardiac Variant;   Right Ventricular Hypertrophy
Intervention:
30 Completed Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study
Condition: Fabry Disease
Intervention: Drug: AT1001
31 Recruiting Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl
32 Completed Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy
Condition: Focus of Study: Prevalence of Fabry Disease in CKD Population
Intervention:
33 Completed
Has Results
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Agalsidase alfa
34 Active, not recruiting Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Biological: agalsidase
35 Completed A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Agalsidase beta (Fabrazyme)
36 Recruiting A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Biological: agalsidase alfa
37 Completed An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: Replagal agalsidase alfa;   Drug: Replagal
38 Recruiting Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Conditions: Fabry Disease;   Cerebrovascular Accident
Intervention: Other: No intervention
39 Recruiting Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
Condition: Fabry Disease
Intervention:
40 Completed Antiproteinuric Agents and Fabry Disease
Conditions: Fabry Disease;   Proteinuria
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years